Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 309-316

  Marr, Kieren A ^a,b,e   Seidel, Kristy ^a   White, Theodore C ^b,c   Bowden, Raleigh A ^a,b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Department of Medicine ^*  (United States)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d Providence Seattle Medical Center   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033955216     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315193     Document Type: Article

References (32)

1. 1. Goodrich JM, Reed C, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164:731-40.
2. 2. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17:10-3.
3. 3. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
4. 4. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
5. 5. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-7.
6. 6. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37:1847-9.
7. 7. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20:115-25.
8. 8. Merz W, Karp J, Schron D, Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986; 24:581-4.
9. 9. Iwen PC, Kelly DM, Reed EC, Hinrichs SH. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis 1995; 20:342-7.
10. 10. Kunova A, Trupl J, Demitrovicova A, et al. Eight-year surveillance of non-albicans Candida spp. in an oncology department prior to and after fluconazole had been introduced into antifungal prophylaxis. Microb Drug Resist 1997; 3:283-7.
11. 11. Clift R, Buckner C, Thomas E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84:2036-43.
12. 12. Buckner C, Cliff R. Appelbaum F, et al. Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. Bone Marrow Transplant 1991; 7(Suppl 2):6-8.
13. 13. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88:4063-71.
14. 14. Patterson TF, Revankar SG, Kirkpatrick WR, et al. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol 1996; 34:1794-7.
15. 15. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A. Wayne, PA: NCCLS, 1997.
16. 16. Goodrich J, Bowden R, Fisher L, Keller C, Schoch G, Meyers J. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118:173-8.
17. 17. Goodrich J, Mori M, Gleaves C, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic marrow transplant. N Engl J Med 1991; 325:1601-7.
18. 18. Hadley S, Samore M, Lewis W, Jenkins R, Karchmer A, Hammer S. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporin or FK 506 as primary immunosuppression. Transplantation 1995; 59:851-9.
19. 19. Krcmery V, Oravcova E, Spanik S, et al. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. J Antimicrob Chemother 1998; 41:373-80.
20. 20. Abi-Said D, Anaissie E, Hzun O, Rand I, Pinzcowski H, Vartirarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-8.
21. 21. Chandrasekar P, Gatny C. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. J Antimicrob Chemother 1994; 33:309-18.
22. 22. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11:382-402.
23. 23. Marr KA, White TC, van Burik JAH, Bowden RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997; 25: 908-10.
24. 24. Nolte FS, Parkinson T, Falconer DJ, et al. Isolation and characterization of fluconazole-and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 41: 196-9.
25. 25. Mori T, Matsumura M, Kanamaru Y, et al. Myelofibrosis complicated by infection due to Candida albicans: emergence of resistance to agents during therapy. Clin Infect Dis 1997; 25:1470-1.
26. 26. Husni R, Gordon S, Longworth D, et al. Cytomegalovirus is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26:753-5.
27. 27. Salzberger B, Bowden R, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997; 90:2502-8.
28. 28. Sparrelid E, Hagglund H, Remberger M, et al. Bacteremia during the aptastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998; 22:795-800.
29. 29. Guiot HF, Fibbe WE, van Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18:525-32.
30. 30. Khan A, Slifer T, Remington J. Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob Agents Chemother 1998; 42: 1713-7.
31. 31. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N, McGrave D. Candida infections in bone marrow transplant patents. Bone Marrow Transplant 1991; 8:177-84.
32. 32. Schoofs A, Odds FC, Colebunders R, Ieven M, Wouters L, Goossens H. Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Antimicrob Agents Chemother 1997; 41:1625-35.